Background and Purpose
Doxorubicin is a broad-spectrum antineoplastic agent; however, its genotoxic/cytotoxic effects limit its clinical application. Dimethyl Fumarate is an FDA-approved to treat multiple sclerosis shown to have antioxidant, anti-inflammatory and antimutagenic effects via activating Nrf2 pathway. The present study aimed to investigate the possible protective effect of DMF against doxorubicin-induced chromosomal and DNA damage in rat bone marrow cells.